{"id":"hepatitis-a-control","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Injection site soreness or erythema"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fatigue"},{"rate":"5-10","effect":"Myalgia"},{"rate":"1-5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) hepatitis A virus particles that trigger both humoral and cellular immune responses. Upon vaccination, the body produces specific antibodies (primarily IgG) that neutralize the virus and provide long-term protection against hepatitis A infection. This is a control vaccine used as a reference standard in clinical trials.","oneSentence":"This inactivated hepatitis A vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protective immunity against infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:40.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A virus infection in susceptible populations"}]},"trialDetails":[{"nctId":"NCT05861674","phase":"PHASE2","title":"A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection","status":"COMPLETED","sponsor":"Huahui Health","startDate":"2023-06-16","conditions":"Chronic Hepatitis Delta Virus Infection","enrollment":101},{"nctId":"NCT07491848","phase":"","title":"Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D","status":"RECRUITING","sponsor":"Research Center of Periodontal-Systemic Interactions","startDate":"2026-02-15","conditions":"HEPATITIS B CHRONIC, Hepatitis D, Periodontitis","enrollment":25},{"nctId":"NCT00001352","phase":"","title":"Fungal Infection Susceptibility","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1993-04-01","conditions":"Cryptococcal Infection, Cryptococcal Pneumonia, Pulmonary Cryptococcosis","enrollment":800},{"nctId":"NCT06364930","phase":"PHASE4","title":"SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-03-26","conditions":"Chronic Hepatitis B","enrollment":412},{"nctId":"NCT07481032","phase":"NA","title":"Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-04-01","conditions":"Cirrhosis, Liver, Hepatocellular Carcinoma (HCC), HEPATITIS B CHRONIC","enrollment":1034},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":"Hepatitis B Virus Infection","enrollment":48},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT07389044","phase":"PHASE1","title":"A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B","status":"RECRUITING","sponsor":"IntegerBio","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT06603311","phase":"NA","title":"Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hannover Medical School","startDate":"2024-09-30","conditions":"Compensated Liver Disease (Disorder), Hepatitis D, Chronic","enrollment":20},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT04704830","phase":"PHASE3","title":"R21/Matrix-M in African Children Against Clinical Malaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2021-04-29","conditions":"Malaria","enrollment":4800},{"nctId":"NCT04555434","phase":"PHASE1, PHASE2","title":"Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH","status":"COMPLETED","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2020-09-20","conditions":"Non-Alcoholic Fatty Liver Disease, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","enrollment":89},{"nctId":"NCT04804072","phase":"NA","title":"INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2021-06-02","conditions":"HIV Infections, Drug Use, Opioid Use","enrollment":447},{"nctId":"NCT07422948","phase":"NA","title":"Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-05","conditions":"Acute on Chronic Liver Failure","enrollment":113},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT03217422","phase":"PHASE2, PHASE3","title":"ADCC Mediated B-Cell dEpletion and BAFF-R Blockade","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-15","conditions":"Autoimmune Hepatitis","enrollment":68},{"nctId":"NCT05653232","phase":"NA","title":"Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-04-19","conditions":"HCV","enrollment":120},{"nctId":"NCT05897099","phase":"NA","title":"Comprehensive HIV and Harm Prevention Via Telehealth","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-10-07","conditions":"HIV Infections","enrollment":350},{"nctId":"NCT07412236","phase":"PHASE3","title":"A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":"Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B","enrollment":1208},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT07404566","phase":"","title":"Utility of MicroRNAs for Diagnosing Hepatocellular Carcinoma in Hepatitis C Patients","status":"COMPLETED","sponsor":"Benha University","startDate":"2025-08-15","conditions":"Hepatocellular Carcinoma","enrollment":84},{"nctId":"NCT07394309","phase":"PHASE1","title":"Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-02-15","conditions":"Liver Fibrosis","enrollment":30},{"nctId":"NCT03567174","phase":"NA","title":"Building on Needle Exchange to Optimize Prevention & Treatment","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-06-22","conditions":"Intravenous Drug Usage, HIV/AIDS","enrollment":720},{"nctId":"NCT06963710","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)","status":"RECRUITING","sponsor":"Aligos Therapeutics","startDate":"2025-07-15","conditions":"Chronic Hepatitis B Infection","enrollment":200},{"nctId":"NCT06497504","phase":"PHASE2","title":"Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-17","conditions":"Hepatitis B","enrollment":157},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06649266","phase":"PHASE2","title":"Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ribocure Pharmaceuticals AB","startDate":"2024-08-21","conditions":"Chronic Hepatitis D","enrollment":14},{"nctId":"NCT05208697","phase":"NA","title":"Tele-Harm Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-10","conditions":"IV Drug Usage, HIV Infections, Hepatitis C","enrollment":100},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05856890","phase":"PHASE1","title":"HepB mAb19 in Individuals With Chronic Hepatitis B Infection","status":"RECRUITING","sponsor":"Rockefeller University","startDate":"2023-08-07","conditions":"Hepatitis b Virus, Hepatitis B","enrollment":37},{"nctId":"NCT07378761","phase":"PHASE2","title":"Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-02","conditions":"Immune-Mediated Cholestasis","enrollment":94},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT05147090","phase":"PHASE4","title":"Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-01-02","conditions":"Chronic Hepatitis b, NAFLD, Cirrhosis","enrollment":106},{"nctId":"NCT07357636","phase":"","title":"Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Shantou University Medical College","startDate":"2019-01-10","conditions":"Solid Tumor, Immune-Related Adverse Events, Immunotherapy Toxicity","enrollment":940},{"nctId":"NCT06644417","phase":"PHASE2","title":"Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-14","conditions":"HBV Infection With LLV","enrollment":122},{"nctId":"NCT07090759","phase":"PHASE3","title":"To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment","status":"RECRUITING","sponsor":"Fujian Akeylink Biotechnology Co., Ltd.","startDate":"2025-07-24","conditions":"Chronic Hepatitis b","enrollment":526},{"nctId":"NCT07037277","phase":"PHASE3","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-06-02","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection","enrollment":880},{"nctId":"NCT07345624","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":80},{"nctId":"NCT07345611","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":60},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":"Hepatitis B","enrollment":122},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT05569759","phase":"PHASE2","title":"A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)","status":"COMPLETED","sponsor":"Kezar Life Sciences, Inc.","startDate":"2023-05-23","conditions":"Autoimmune Hepatitis","enrollment":24},{"nctId":"NCT02065336","phase":"PHASE2","title":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2014-03","conditions":"Hepatitis B, Chronic","enrollment":58},{"nctId":"NCT04327440","phase":"","title":"RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2020-02-04","conditions":"Malaria, Malaria Vaccine, Insecticide-treated Bednets","enrollment":1691},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT07328711","phase":"EARLY_PHASE1","title":"Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"Chronic Hepaititis B","enrollment":132},{"nctId":"NCT06624176","phase":"NA","title":"ShotBlocker During Intramuscular Injection Randomized Control Trial","status":"RECRUITING","sponsor":"Lauren Fortier","startDate":"2024-01-10","conditions":"Neonatal Pain","enrollment":200},{"nctId":"NCT00200343","phase":"PHASE3","title":"Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2002-07","conditions":"Chronic Hepatitis C","enrollment":596},{"nctId":"NCT07309380","phase":"PHASE3","title":"Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D","status":"NOT_YET_RECRUITING","sponsor":"Shanghai HEP Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Hepatitis D, Chronic","enrollment":150},{"nctId":"NCT05276297","phase":"PHASE2","title":"A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Hepatitis B, Chronic","enrollment":174},{"nctId":"NCT07122219","phase":"NA","title":"Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-10-01","conditions":"HIV, Hepatitis C Virus (HCV)","enrollment":548},{"nctId":"NCT07295873","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-30","conditions":"Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)","enrollment":64},{"nctId":"NCT06799702","phase":"NA","title":"Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)","status":"NOT_YET_RECRUITING","sponsor":"University of Georgia","startDate":"2026-08-01","conditions":"HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), Opioid Use Disorder","enrollment":50},{"nctId":"NCT07085377","phase":"NA","title":"Autonomous Methadone Delivery System by Nurses","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-12-08","conditions":"Opioid Use Disorder (OUD), Addictology","enrollment":182},{"nctId":"NCT07282249","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Grand Theravac Life Sciences (Nanjing) Co., Ltd.","startDate":"2025-12-31","conditions":"Chronic hepatitisB","enrollment":630},{"nctId":"NCT07031219","phase":"NA","title":"HIV/HBV/HCV Triple Screening in Primary Care","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-15","conditions":"HIV, HBV (Hepatitis B Virus), HCV","enrollment":50},{"nctId":"NCT06855836","phase":"NA","title":"Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-03-03","conditions":"Overdose","enrollment":588},{"nctId":"NCT07275918","phase":"PHASE1","title":"SA1211 Injection Phase 1 Study","status":"RECRUITING","sponsor":"Suzhou Siran Biotechnology Co.,Ltd.","startDate":"2025-11-25","conditions":"Chronic Hepatitis B","enrollment":80},{"nctId":"NCT04684914","phase":"PHASE2","title":"HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Altimmune, Inc.","startDate":"2020-12-26","conditions":"Hepatitis B, Chronic","enrollment":87},{"nctId":"NCT06868264","phase":"PHASE3","title":"C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-07","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION","enrollment":880},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT03224949","phase":"","title":"Comparison of ALD, NASH, and Healthy Control Patients","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2017-06-19","conditions":"ALD - Alcoholic Liver Disease","enrollment":500},{"nctId":"NCT06591468","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics","status":"ENROLLING_BY_INVITATION","sponsor":"Han Ying","startDate":"2024-10-30","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":244},{"nctId":"NCT07253220","phase":"NA","title":"TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-01","conditions":"Hepatitis B, Hepatocellular Carcinoma (HCC)","enrollment":120},{"nctId":"NCT03826433","phase":"PHASE1","title":"hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis","status":"RECRUITING","sponsor":"Sclnow Biotechnology Co., Ltd.","startDate":"2018-10-01","conditions":"Hepatitis B","enrollment":20},{"nctId":"NCT04536337","phase":"PHASE1","title":"A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects","status":"COMPLETED","sponsor":"Aligos Therapeutics","startDate":"2020-10-22","conditions":"Chronic Hepatitis B","enrollment":165},{"nctId":"NCT06470997","phase":"","title":"Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2024-07-17","conditions":"Immune-mediated Hepatitis","enrollment":60},{"nctId":"NCT07238530","phase":"","title":"Insulin Resistance Among Hepatitis C Infected Children","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2015-09","conditions":"This Study is to Assess Occurence of Insulin Resistance Among Hepatits C Infected Children Whether Thalassemic or Survivors of Childhood Malignancy","enrollment":90},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT05797714","phase":"NA","title":"The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-06-08","conditions":"HBV Infection, Chronic Hepatitis b","enrollment":200},{"nctId":"NCT05824702","phase":"NA","title":"A Social Network Approach for Improving Medication Assisted Treatment and HIV Prevention and Medical Care Among People Who Inject Drugs in Ukraine","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2023-09-20","conditions":"HIV","enrollment":241},{"nctId":"NCT02452528","phase":"PHASE2","title":"Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT07168356","phase":"PHASE1","title":"A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-09-16","conditions":"Hepatitis B","enrollment":32},{"nctId":"NCT03981445","phase":"NA","title":"Integrated HIV Prevention and HCV Care for PWID","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2019-11-14","conditions":"HIV Prevention, HCV, Opioid Use","enrollment":446},{"nctId":"NCT07190742","phase":"PHASE2","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grand Theravac Life Sciences (Nanjing) Co., Ltd.","startDate":"2023-06-01","conditions":"Chronic Hepatitis B Virus","enrollment":80},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT07185152","phase":"NA","title":"The Effect of Mechanical Vibration and Flick Tapping Methods in Reducing Pain in Infant Vaccination","status":"COMPLETED","sponsor":"Berrin GOGER","startDate":"2024-04-29","conditions":"Health Knowledge, Attitudes, Practice, Health Behavior","enrollment":80},{"nctId":"NCT03038802","phase":"PHASE1, PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":"Chronic Hepatitis b","enrollment":40},{"nctId":"NCT04225715","phase":"PHASE2","title":"A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-05","conditions":"Hepatitis B, Chronic","enrollment":281},{"nctId":"NCT07179653","phase":"PHASE2","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grand Theravac Life Sciences (Nanjing) Co., Ltd.","startDate":"2025-01-22","conditions":"HBV Infection","enrollment":48},{"nctId":"NCT03155906","phase":"NA","title":"Integrated Treatment of Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2017-05-18","conditions":"Hepatitis C, Chronic, Opioid Dependence, on Agonist Therapy","enrollment":298},{"nctId":"NCT07176741","phase":"","title":"LiverTREM-1: Hepatic TREM-1 Expression and Prognosis in Severe Alcoholic Hepatitis","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-10-01","conditions":"Severe Alcoholic Hepatitis","enrollment":300},{"nctId":"NCT05543642","phase":"PHASE4","title":"The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2022-10-11","conditions":"Rheumatic Diseases","enrollment":129},{"nctId":"NCT03859687","phase":"PHASE1","title":"Trial of Antibody Responses by Vitamin Supplementation","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-19","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT02473341","phase":"PHASE3","title":"Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dayanand Medical College and Hospital","startDate":"2017-11-14","conditions":"Alcoholic Hepatitis","enrollment":174},{"nctId":"NCT07059403","phase":"PHASE1","title":"A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults","status":"RECRUITING","sponsor":"Chimivac INC","startDate":"2025-08-19","conditions":"Chronic Hepatitis B Infection","enrollment":36},{"nctId":"NCT01718301","phase":"PHASE3","title":"HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin","status":"TERMINATED","sponsor":"Anna Cruceta","startDate":"2013-03-10","conditions":"Hepatitis C, HIV Infections, COINFECTION","enrollment":108},{"nctId":"NCT05330455","phase":"PHASE1, PHASE2","title":"Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-04-14","conditions":"Hepatitis B","enrollment":74},{"nctId":"NCT07126041","phase":"NA","title":"Scalable Public Health Empowerment, Research, and Education Sites (SPHERES)","status":"NOT_YET_RECRUITING","sponsor":"Oxford University Clinical Research Unit Indonesia","startDate":"2025-08-14","conditions":"Pregnancy, Neonatal Mortality, Tuberculosis","enrollment":1750000},{"nctId":"NCT07120464","phase":"","title":"Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations","status":"RECRUITING","sponsor":"Liaoning Chengda Biotechnology CO., LTD","startDate":"2025-08-15","conditions":"Rabies Exposure, Immunocompromised, Chronic Disease","enrollment":180},{"nctId":"NCT03949764","phase":"PHASE4","title":"The Kentucky Viral Hepatitis Treatment Study","status":"COMPLETED","sponsor":"Jennifer Havens","startDate":"2019-09-23","conditions":"Hepatitis C, Opioid-Related Disorders, Injection Drug Use","enrollment":374},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT07095855","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2025-08","conditions":"Chronic Hepatitis B","enrollment":1300},{"nctId":"NCT06990776","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects","status":"WITHDRAWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-07-09","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT03135886","phase":"NA","title":"Project I Test: Implementing HIV Testing in Opioid Treatment Programs","status":"RECRUITING","sponsor":"Columbia University","startDate":"2017-06-12","conditions":"HIV/AIDS, Hepatitis C, Substance Use Disorders","enrollment":418},{"nctId":"NCT06537414","phase":"PHASE2","title":"A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-11","conditions":"Chronic Hepatitis B Virus Infection, Hepatitis B","enrollment":283},{"nctId":"NCT06384131","phase":"PHASE1","title":"A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2024-06-04","conditions":"Chronic Hepatitis B","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1582,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hepatitis A (control)","genericName":"Hepatitis A (control)","companyName":"International Vaccine Institute","companyId":"international-vaccine-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Hepatitis A is a viral infection that can be prevented through vaccination, with vaccines available for other conditions such as Condylomata Acuminata, Chickenpox, Dengue Fever, Dengue Hemorrhagic Fever, and Influenza Human. Hepatitis A vaccines do not exist in the provided information, but Hepatitis B vaccines, which are binding agents that target the surface antigen (HBsAg), are available for other conditions.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}